BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gonçalves A, Lemenuel-Diot A, Cosson V, Jin Y, Feng S, Bo Q, Guedj J. What drives the dynamics of HBV RNA during treatment? J Viral Hepat 2021;28:383-92. [PMID: 33074571 DOI: 10.1111/jvh.13425] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Sotty J, Bablon P, Lekbaby B, Augustin J, Girier-Dufournier M, Langlois L, Dorival C, Carrat F, Pol S, Fontaine H, Sarica N, Neuveut C, Housset C, Kremdsorf D, Schnuriger A, Soussan P. Diversity of the nucleic acid forms of circulating HBV in chronically infected patients and its impact on viral cycle. Hepatol Int 2022. [PMID: 35927368 DOI: 10.1007/s12072-022-10389-6] [Reference Citation Analysis]
2 Reinharz V, Churkin A, Dahari H, Barash D. Advances in Parameter Estimation and Learning from Data for Mathematical Models of Hepatitis C Viral Kinetics. Mathematics 2022;10:2136. [DOI: 10.3390/math10122136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Reinharz V, Ishida Y, Tsuge M, Durso-Cain K, Chung TL, Tateno C, Perelson AS, Uprichard SL, Chayama K, Dahari H. Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric Mice. J Virol 2021;95:e0049220. [PMID: 33910953 DOI: 10.1128/JVI.00492-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
4 Wu IC, Liu WC, Chiu YC, Chiu HC, Cheng PN, Chang TT. Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss. Microorganisms 2021;9:1146. [PMID: 34073483 DOI: 10.3390/microorganisms9061146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Cosson V, Feng S, Jaminion F, Lemenuel-Diot A, Parrott N, Paehler A, Bo Q, Jin Y. How Semiphysiological Population Pharmacokinetic Modeling Incorporating Active Hepatic Uptake Supports Phase II Dose Selection of RO7049389, A Novel Anti-Hepatitis B Virus Drug. Clin Pharmacol Ther 2021;109:1081-91. [PMID: 33523474 DOI: 10.1002/cpt.2184] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Perelson AS, Ke R. Mechanistic Modeling of SARS-CoV-2 and Other Infectious Diseases and the Effects of Therapeutics. Clin Pharmacol Ther 2021;109:829-40. [PMID: 33410134 DOI: 10.1002/cpt.2160] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 30.0] [Reference Citation Analysis]
7 Gonçalves A, Lemenuel-Diot A, Guedj J. Reply to: 'Early HBV RNA kinetics under NA treatment may reveal new insights into HBV RNA dynamics and NA mode of action'. J Viral Hepat 2021;28:689-90. [PMID: 33462946 DOI: 10.1111/jvh.13470] [Reference Citation Analysis]
8 Dahari H, Shlomai A, Cotler SJ. Early HBV RNA kinetics under NA treatment may reveal new insights into HBV RNA dynamics and NA mode of action-more detailed kinetic studies are needed. J Viral Hepat 2021;28:687-8. [PMID: 33386635 DOI: 10.1111/jvh.13463] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]